Reducing costs in atopic dermatitis.

Dermatol Ther

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Published: November 2022

Atopic dermatitis (AD) is a common relapsing inflammatory skin condition associated with a high economic burden due to its chronicity and multitude of direct and indirect treatment costs. AD disproportionately impacts children and minority populations, and treatment choices are cost-prohibitive for many patients. Our objective was to describe the treatment and management of AD from a cost-conscious perspective. A review of the literature was conducted with PubMed using the following keywords: AD, cost, medications, treatment, management, efficacy, adherence, education, and prophylactic. The use of moisturizers prophylactically in high-risk infants who have yet to develop AD may reduce incidence of disease and associated costs. Increasing patient medication adherence and moisturizing between flares also reduces costs in AD. The use of corticosteroids as the first-line treatment is efficacious and cost-effective for mild cases of AD, however, in severe cases of AD corticosteroids alone are not sufficient. Systemic biologics are necessary in some patients with severe cases of AD; however, they are associated with high costs. Phototherapy, through portable home units, tanning beds, and natural sunlight are cost-effective alternatives. Effective management of AD improves with education programs for both the patient and their family, reducing long-term costs in the management of this disease. Reducing AD treatment costs requires consideration of prophylactic therapies, patient education, and should differ based on the severity of disease. A multifaceted approach to AD treatment reduces costs and health-care barriers.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.15849DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
8
associated high
8
treatment costs
8
treatment management
8
reduces costs
8
severe cases
8
treatment
7
costs
7
reducing costs
4
costs atopic
4

Similar Publications

Methotrexate for atopic dermatitis: The right dosing and best-performance administration route.

J Eur Acad Dermatol Venereol

February 2025

CIRI (International Center for Infectiology Research) INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1 CNRS UMR5308, Lyon, France.

View Article and Find Full Text PDF

Use of D-Squame as a Minimally Invasive Technique to Evaluate Skin Immune Response Biomarkers in Canine Atopic Dermatitis.

Vet Sci

December 2024

Interactions Cells Environment, 2016. A104, VetAgro Sup, Dermatology Department, 69280 Marcy L'étoile, France.

Evaluation of skin inflammation biomarkers in canine atopic dermatitis (AD) currently requires skin biopsies. Tape stripping has been shown to be a reliable technique to study biomarkers in the stratum corneum (SC) in humans. The aim of this study was to assess the immune response and identify biomarkers in the SC of dogs with canine AD using D-squame as a minimally invasive technique.

View Article and Find Full Text PDF

Cannabinoid compounds have potential as treatments for a variety of conditions, with cannabigerol (CBG) being known for its anti-inflammatory properties. In this study, we investigated the effects of CBG in a cellular model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). In the cellular model, we confirmed the cytotoxicity of CBG and downregulated the expression of inflammatory markers , , , and ( < 0.

View Article and Find Full Text PDF

Introduction: Atopic dermatitis (AD), a common dermatological condition, is often associated with significant economic and social burdens. Despite extensive studies globally, there is a gap in understanding the impact of this condition in Romania. This study evaluated the economic burden of AD in Romania, considering both direct and indirect costs.

View Article and Find Full Text PDF

Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.

Indian Dermatol Online J

December 2024

Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.

Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!